Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings,National Institute of Allergy and Infectious Diseases,Bethesda, Maryland,USA, May 21, 2015 |
| |
| Affiliation: | 1. Research Institute for Health Sciences, Chiang Mai University, 110 Intavaroros Road, Sriphum, Chiang Mai 50200, Thailand;2. HJF-DAIDS, a Division of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, 5601 Fishers Lane, 8C27 Rockville, MD 20892-9832, USA;3. Vaccine Translational Research Branch, Vaccine Research Program, Division of AIDS, NIAID, NIH, 5601 Fishers Lane, MSC 9829, Rockville, MD 20892-9829, USA;1. Real-time Syndromic Surveillance Team, National Infection Service, Public Health England, 1st Floor, 5 St Philips Place, Birmingham B3 2PW, United Kingdom;2. The Phoenix Partnership (TPP), TPP House, 129 Low Lane, Horsforth, Leeds LS18 5PX, United Kingdom;3. Public Health England West Midlands, 6th Floor, 5 St Philips Place, Birmingham B3 2PW, United Kingdom;4. Immunisation, Hepatitis and Blood Safety Department, National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, United Kingdom;5. Royal College of General Practitioners Research and Surveillance Centre, University of Surrey, Section of Clinical Medicine and Ageing, Guildford, Surrey GU2 7XH, United Kingdom;1. MRC/UVRI Uganda Research Unit on AIDS; c/o Uganda Virus Research Institute, Entebbe, Uganda;2. National Institute for Communicable Diseases, Johannesburg, South Africa;7. Aalto University School of Science, Department of Mathematics, and Systems Analysis, Finland;9. Genomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, NIAID, NIH, Hamilton, MT, USA;1. MRC/UVRI Uganda Research Unit on AIDS, c/o Uganda Virus Research Institute, Entebbe, Uganda;2. National Institute for Communicable Diseases, Johannesburg, South Africa;3. Center for the AIDS Program of Research in South Africa (CAPRISA), South Africa;8. University of the Witwatersrand, Johannesburg, South Africa;4. Laboratory of Immunoregulation, Division of Intramural Research, NIAID, NIH, Bethesda, USA;5. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;6. London School of Hygiene and Tropical Medicine, Department of Clinical Research, London, UK;1. Adult Vaccines, Merck USA, West Point, PA, United States;2. Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, United States;3. Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, United States;1. School of Public Health and Community Medicine, UNSW Medicine, The University of New South Wales, Sydney, NSW, Australia;2. National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia;3. Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia;1. Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA;2. Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, USA;3. inVentiv Health Clinical, 504 Carnegie Center, Princeton, NJ 08540, USA;4. Pfizer Vaccine Clinical Research and Development, Pfizer Pharma GmbH, Linkstrasse 10, 10785 Berlin, Germany;5. Pfizer Vaccine Clinical Research and Development, Pfizer Inc., 401 N Middletown Road, Pearl River, NY 10965, USA;6. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 85025, Israel;1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), United States;2. HIV Incidence and Case Surveillance Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), United States;3. Flexcare Medical Staffing, Roseville, CA, United States |
| |
| Abstract: | On May 21st, 2015, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop on delivery devices for nucleic acid (NA) as vaccines in order to review the landscape of past and future technologies for administering NA (e.g., DNA, RNA, etc.) as antigen into target tissues of animal models and humans. Its focus was on current and future applications for preventing and treating human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) disease, among other infectious-disease priorities. Meeting participants presented the results and experience of representative clinical trials of NA vaccines using a variety of alternative delivery devices, as well as a broader group of methods studied in animal models and at bench top, to improve upon the performance and/or avoid the drawbacks of conventional needle-syringe (N–S) delivery. The subjects described and discussed included (1) delivery targeted into oral, cutaneous/intradermal, nasal, upper and lower respiratory, and intramuscular tissues; (2) devices and techniques for jet injection, solid, hollow, and dissolving microneedles, patches for topical passive diffusion or iontophoresis, electroporation, thermal microporation, nasal sprayers, aerosol upper-respiratory and pulmonary inhalation, stratum-corneum ablation by ultrasound, chemicals, and mechanical abrasion, and kinetic/ballistic delivery; (3) antigens, adjuvants, and carriers such as DNA, messenger RNA, synthesized plasmids, chemokines, wet and dry aerosols, and pollen-grain and microparticle vectors; and (4) the clinical experience and humoral, cellular, and cytokine immune responses observed for many of these target tissues, technologies, constructs, and carriers. This report summarizes the presentations and discussions from the workshop (https://web.archive.org/web/20160228112310/https://www.blsmeetings.net/NucleicAcidDeliveryDevices/), which was webcast live in its entirety and archived online (http://videocast.nih.gov/summary.asp?live=16059). |
| |
| Keywords: | HIV DNA Vaccination Delivery Technology Cutaneous Intradermal Intranasal Respiratory Microneedles Patch Electroporation Laser Ultrasound Jet Injection |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
